Last reviewed · How we verify

NCT04849780

Evaluation of Dryness in a Silicone Hydrogel Daily Disposable Contact Lens

Completed NA Results posted Last updated 10 October 2022
What this trial tests

NA trial testing ACUVUE Oasys 1-Day in Visual Acuity in 95 participants. Completed in 12 August 2021.

Timeline
17 April 2021
Primary endpoint
12 August 2021
12 August 2021

Quick facts

Lead sponsorJohnson & Johnson Vision Care, Inc.
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment95
Start date17 April 2021
Primary completion12 August 2021
Estimated completion12 August 2021
Sites9 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Johnson & Johnson Vision Care, Inc. — full company profile →

Who can join

Adults 18 to 59, any sex, with Visual Acuity. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Change From Baseline Comfort Score Primary · Up to 2-Week Follow-up

Comfort was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120. The change from baseline was calculated as 2-week follow-up minus bas

GroupValue95% CI
Arm 128.99± 26.766
Arm 2 (Subjects' Own Contact Lens)-0.29± 10.245
Change From Baseline CLDEQ-8 Score Secondary · Up to 2-Week Follow-up

The CLDEQ-8 is a validated outcome measure for soft contact lenses wearers. It has been highly correlated with habitual baseline status and change in overall opinion when subjects are refit with contact lenses. A CLDEQ-8 total score of ≥12 is proposed to identify contact lens wearers who could benefit from clinical management of their contact lens related symptoms. A three-point change in CLDEQ-8 total scores has also been shown to be clinically important. This study will include the symptomatic subjects who will have a CLDEQ total score of ≥15. CLDEQ-8 scores range from 0 to 30 where, higher

GroupValue95% CI
Arm 1-10.83± 6.631
Arm 2 (Subjects' Own Contact Lens)-1.23± 3.638
Comfort Score Secondary · 2-Week Follow-up

Comfort was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120. The average comfort score was reported for each group within Arm 2 on

GroupValue95% CI
Arm 2 (Senofilcon A)55.88± 25.721
Arm 2 (Subjects' Own Contact Lens)29.69± 13.849
CLDEQ-8 Score Secondary · 2-Week Follow-up

The CLDEQ-8 is a validated outcome measure for soft contact lenses wearers. It has been highly correlated with habitual baseline status and change in overall opinion when subjects are refit with contact lenses. A CLDEQ-8 total score of ≥12 is proposed to identify contact lens wearers who could benefit from clinical management of their contact lens related symptoms. A three-point change in CLDEQ-8 total scores has also been shown to be clinically important. This study will include the symptomatic subjects who will have a CLDEQ total score of ≥15. CLDEQ-8 scores range from 0 to 30 where, higher

GroupValue95% CI
Arm 2 (Senofilcon A)12.46± 6.078
Arm 2 (Subjects' Own Contact Lens)21.18± 3.698

Adverse events — posted to ClinicalTrials.gov

Time frame: Throughout the entire duration of the study. For subject in Arm 1 their study duration was approximately 2-weeks while subjects in Arm 2 study duration was approximately 1-month.. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Senofilcon A
Serious: 0/88 (0%)
Deaths: 0/88
Nelfilcon A
Serious: 0/11 (0%)
Deaths: 0/11
Delfilcon A
Serious: 0/10 (0%)
Deaths: 0/10
Somofilcon A
Serious: 0/5 (0%)
Deaths: 0/5
Stenofilcon A
Serious: 0/2 (0%)
Deaths: 0/2
Etafilcon A
Serious: 0/17 (0%)
Deaths: 0/17
Other adverse events (1 terms — click to expand)

ReactionSystemSenofilcon ANelfilcon ADelfilcon ASomofilcon AStenofilcon AEtafilcon A
Covid - 19Infections and infestations

Data from ClinicalTrials.gov NCT04849780 adverse events section.

Sponsor's own description

This is a multi-site, randomized, bilateral, dispensing, parallel design study with two arms to evaluate contact lens related dry eye symptoms and subjective comfort.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of ACUVUE Oasys 1-Day

Trials testing the same drug.

Other recruiting trials for Visual Acuity

Currently open trials in the same condition.

Other Johnson & Johnson Vision Care, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04849780.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing